GlassScriptPhysician profile
Maria Bogaert
NPI 1790756534
$8,225.55
in general payments reported to CMS, 2019-2025
26 companies · $2,052 in 2025
The $2,052 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.52 · 2020: $116 · 2021: $391 · 2022: $1,272 · 2023: $2,092 · 2024: $2,252 · 2025: $2,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,381 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,381.36 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,752.79 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $918.91 | 2021-2025 | Tremfya, Stelara, Remicade |
| E.R. Squibb & Sons, L.L.C. | $761.62 | 2022-2025 | Sotyktu |
| Ucb, INC. | $760.92 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $546.63 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $443.65 | 2021-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $395.81 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $337.27 | 2020-2025 | Ilumya, Winlevi, Odomzo |
| Dermavant Sciences, INC. | $316.36 | 2022-2024 | Vtama |
| Amgen INC. | $308.23 | 2022-2025 | Otezla, Enbrel, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $295.38 | 2022-2025 | Siliq, Cabtreo, Targretin |
| Pfizer INC. | $243.55 | 2022-2025 | |
| Galderma Laboratories, L.P. | $179.55 | 2023-2025 | Oracea, Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $161.76 | 2024-2025 | Zoryve |
| Incyte Corporation | $152.93 | 2021-2025 | Opzelura |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $150.74 | 2021-2025 | |
| Lilly USA, LLC | $143.04 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Organon LLC | $80.83 | 2025 | Vtama |
| Mallinckrodt Hospital Products INC. | $60.47 | 2024-2025 | Acthar |
| Organogenesis INC. | $58.85 | 2020-2024 | Puraply |
| Botanix Sb INC | $41.38 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.78 | 2023-2024 | Spevigo |
| Journey Medical Corporation | $30.50 | 2023 | |
| Genentech USA, INC. | $18.93 | 2023 | Xolair |
| Almirall LLC | $17.29 | 2023 | Klisyri |
| Kowa Pharmaceuticals America, INC. | $16.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Bogaert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.